In a significant triumph for the scientific community, three researchers from the Broad Institute of MIT and Harvard have been recognized by the National Institutes of Health (NIH) for their commitment to tackling some of the most complex challenges in biomedical science. The NIH recently announced the recipients of its 2024 High-Risk, High-Reward Research Program, a competitive initiative designed to support exceptionally creative scientists pursuing unconventional approaches to medicine.
Among the 58 awardees selected nationwide, Erin Chen and Sam Peng have been granted the prestigious NIH Director’s New Innovator Award—an honor reserved for early-career investigators of extraordinary potential. Meanwhile, JT Neal has been awarded the NIH Director’s Transformative Research Award, which funds projects that challenge existing scientific paradigms and hold the potential to create entirely new fields of inquiry.
These awards, which represent a portion of the $237 million in funding recently distributed by the NIH, serve as a testament to the Broad Institute’s role as a global epicenter for interdisciplinary, high-impact research. By fostering environments where high-risk ideas are encouraged, the NIH aims to accelerate the pace of discovery in areas ranging from immunology and structural biology to genomic medicine.
Chronology: A Trajectory of Scientific Excellence
The journey toward these accolades has been characterized by years of rigorous investigation and academic leadership. For the Broad Institute, the recent announcement marks another milestone in a sustained effort to attract and retain the brightest minds in science.
The Rise of New Innovators
Erin Chen, who joined the Broad as a core institute member in 2023, arrived with a distinguished background as both an assistant professor of biology at MIT and an attending dermatologist at Massachusetts General Hospital. Her dual role—bridging the gap between the laboratory bench and the clinical setting—has been pivotal in shaping her research trajectory.
Similarly, Sam Peng joined the Broad as a core institute member in 2022. As an assistant professor of chemistry at MIT, Peng has spent the last two years establishing a laboratory focused on the intersection of single-molecule biophysics and cellular signaling. His arrival at the Broad was strategic, positioning him within a collaborative ecosystem that thrives on technical innovation.
A Decade of Transformation
JT Neal’s career at the Broad Institute represents a decade of foundational work. Having served the institute for nearly ten years, Neal has evolved from a researcher into a key leader, currently serving as an institute scientist and the director of systems genomics. His appointment as an investigator in the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease has provided him with the institutional support to push the boundaries of functional genomics. Notably, Neal is no stranger to NIH recognition, having already secured a New Innovator Award in 2021—a precursor to his current transformative research endeavor.
Supporting Data: Investigating the Frontiers of Biology
The projects funded by these NIH awards represent the bleeding edge of modern biotechnology. Each researcher is leveraging unique methodologies to address long-standing biological mysteries.
Decoding the Skin Microbiome
Dr. Erin Chen’s New Innovator Award will fund a critical exploration of the skin microbiome. The human skin is home to a vast ecosystem of bacteria, yet the mechanisms by which these microbes communicate with the immune system remain poorly understood. Chen’s research aims to identify how specific skin-resident bacteria trigger T cell responses that effectively combat disease without inciting the harmful inflammation typically associated with immune activation. By understanding the "language" between skin bacteria and T cells, Chen hopes to develop a new class of immunotherapies that could treat skin diseases and systemic conditions with unprecedented precision.
Illuminating GPCR Signaling
Dr. Sam Peng is tackling the elusive mechanics of G-protein-coupled receptors (GPCRs). These proteins are the targets of roughly one-third of all FDA-approved drugs, yet the real-time dynamics of their signaling pathways remain difficult to capture. Through his award, Peng plans to develop novel single-molecule microscopy techniques capable of observing these receptors in action at the nanometer scale. This research is vital; because GPCR dysregulation is linked to everything from cardiovascular disease to neurological disorders, obtaining a clearer, real-time picture of their behavior could open the door to a new generation of targeted therapeutics.
The "Encore" Platform: A Paradigm Shift in Drug Discovery
JT Neal’s Transformative Research Award is backing the development of "Encore," an experimental and computational platform designed to redefine drug discovery for rare genetic diseases. Currently, drug development is a slow, iterative process, often focusing on one disease at a time. Neal’s approach is fundamentally different: Encore will utilize massively parallel functional genomics and single-cell imaging to screen thousands of drugs against hundreds of disease-associated phenotypes simultaneously. By testing over 1.6 million drug-disease combinations in parallel, the platform aims to identify potential cures for rare conditions that have historically been neglected by the pharmaceutical industry due to the high costs and low efficiency of traditional screening methods.
Official Responses and Institutional Significance
The NIH High-Risk, High-Reward program is part of the agency’s Common Fund, which supports research that is "high-risk" because it often lacks the preliminary data required by traditional grant mechanisms, yet holds the potential for "high-reward" impact.
"The projects selected this year are as bold as they are diverse," said an NIH representative in a press release accompanying the announcement. "By investing in these investigators, we are betting on the future of medicine. We are looking for the ‘aha’ moments that can turn the tide on diseases that currently have no effective treatments."
At the Broad Institute, the news has been met with both celebration and a sense of institutional pride. Leadership at the Broad often emphasizes that their core mission is to empower researchers to pursue big, risky questions that traditional funding bodies might overlook. For Chen, Peng, and Neal, the NIH awards validate this institutional philosophy, providing the financial runway necessary to take their research from the conceptual stage to potential clinical application.
Implications: Changing the Landscape of Biomedical Research
The impact of these awards extends far beyond the individual laboratories of the recipients. The work of Chen, Peng, and Neal addresses systemic bottlenecks in modern medicine.
Bridging the Gap Between Basic Science and the Clinic
The projects highlight a growing trend in biomedical research: the integration of advanced computational models with high-throughput experimental data. Whether it is Chen’s focus on the microbiome, Peng’s work on structural biology, or Neal’s large-scale genomic screening, all three projects rely on the "Broad approach"—a synthesis of biology, chemistry, computer science, and engineering.
Democratizing Drug Discovery
JT Neal’s "Encore" platform, in particular, could have profound implications for patient advocacy groups. Rare diseases, while individually uncommon, collectively affect millions of people. By creating a platform that tests millions of drug-disease combinations simultaneously, Neal is effectively "democratizing" the drug discovery process, making it feasible to investigate diseases that were previously considered "undruggable" or commercially non-viable.
Future Outlook
As these researchers begin their projects, the medical community will be watching closely. The NIH’s investment serves as a beacon, signaling to the broader scientific community that the most effective way to solve the world’s most pressing health issues is through bold, unconventional thinking.
For the Broad Institute, the success of Chen, Peng, and Neal reinforces its status as a magnet for global talent. By supporting researchers who are willing to challenge the status quo, the institute ensures that it remains at the forefront of the scientific revolution, constantly pushing the boundaries of what is possible in human health and medicine.
In the coming years, as these projects yield their first sets of data, the insights gained may well provide the roadmap for the next generation of diagnostics and therapies, proving once again that the greatest rewards in science are reserved for those willing to embrace the greatest risks.
About the Author
